Stay updated on Once vs Twice Weekly Carfilzomib in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Once vs Twice Weekly Carfilzomib in Multiple Myeloma Clinical Trial page.

Latest updates to the Once vs Twice Weekly Carfilzomib in Multiple Myeloma Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check41 days agoChange DetectedThe page has been updated to include a new version number (v2.15.0) and the term 'Relapsed or Refractory Multiple Myeloma', while significant details about a clinical study have been removed.SummaryDifference12%
- Check48 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check56 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check92 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.7%
Stay in the know with updates to Once vs Twice Weekly Carfilzomib in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Once vs Twice Weekly Carfilzomib in Multiple Myeloma Clinical Trial page.